GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 13, 2025.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts more than Nifty Midcap 150 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
GSK Pharma reported audited FY25 results (standalone) with revenue from operations rising ~9% YoY to Rs. 3,723 crores, while profit after tax jumped ~57% to Rs. 919 crores — the sharp PAT growth is partly flattered by a one-time VRS charge of Rs. 144 crores in the prior year. Q4 FY25 PAT grew ~35% YoY to Rs. 260 crores on revenue of Rs. 966 crores. Operating cash flow more than doubled to Rs. 1,280 crores, and the balance sheet remains net cash with zero debt and reserves of Rs. 1,780 crores. The Board recommended a final dividend of Rs. 42 per share (up from Rs. 32), with record date May 30, 2025 and AGM on June 27, 2025. Auditors Deloitte Haskins & Sells LLP issued an unmodified opinion. Dr. Sunita Maheshwari was re-appointed as Independent Director, and Parikh & Associates was appointed as Secretarial Auditor for 5 years from FY26.
Higher dividend (31% increase) and strong profit growth reflect healthy shareholder returns, while a clean unmodified audit and robust cash generation support investor confidence. However, underlying revenue growth is modest at ~9%, and the headline PAT jump benefits from a low base — investors should focus on sustainable earnings trajectory.